CLSA India Initiates Coverage With ‘BUY’ Rating On Gland Pharma Share Price

Gland Pharma’s shares jumped on June 21 when brokerage firm CLSA India commenced covering with a ‘buy’ recommendation on the stock, citing the company’s potential to gain from western drug companies’ increasing movement of research and development outsourcing out of China.

“Western corporations diversifying their supply chains provides an enriching environment,” CLSA India wrote in a note. “Indian enterprises have an edge in their access to a huge and low-cost science-literate workforce.”

Also Read :- SEBI Barred AMCs From Offering Bundled Insurance Products With mutual Funds

According to the brokerage company, India’s pharma outsourcing business is expected to increase at an annual rate of 11% over the following four years, reaching a $200 billion sector by 2026. “As innovators seek to reduce R&D expenses and enhance efficiency, outsourcing is expected to accelerate,” CLSA stated.

Despite the fact that Indian firms are hampered by rules, finance, and skill to nurture broad innovation, the brokerage company anticipates companies like Gland Pharma to gain significantly from the rising trend.

Apart from having a diverse global client base, CLSA believes that Gland Pharma has high entry barriers in its respective niche, owing to the high upfront investment in setting up a lab or manufacturing facility, long gestation periods, high switching costs for the innovator, and, most importantly, the ability to protect intellectual property.

Also Read :- Kotak Equities Upgrades HDFC AMC Share Price Target Rating To ‘Add’

Gland Pharma is expected to expand revenues by 15-20% over the next three years, which is faster than its long-term average, according to the brokerage company. “As they consolidate their product offerings and enhance asset utilisation,” the brokerage company added, “we also predict steady margin growth and improvement in return ratios.”

At 10:15 am, shares of Gland Pharma were up 1.8 percent at Rs 2,619.65 on the National Stock Exchange.

Disclaimer :- The views and recommendations made above are those of individual analysts or broking companies, and not of Ours.
We will be happy to hear your thoughts

      Leave a reply

      Share Price India News